サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1726238

アミノグリコシドの市場規模、シェア、動向分析レポート：製品別、投与経路別、用途別、地域別、セグメント予測、2025年～2030年

Aminoglycosides Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 105 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
アミノグリコシドの市場規模、シェア、動向分析レポート：製品別、投与経路別、用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年04月16日
発行: Grand View Research
ページ情報: 英文 105 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アミノグリコシド市場の成長と動向

Grand View Research, Inc.の最新レポートによると、アミノグリコシドの世界市場規模は2030年までに24億5,000万米ドルに達すると予測されています。

市場は2025～2030年にかけてCAGR 4.34％で成長すると予測されています。このような需要の伸びが期待される背景には、抗生物質の大量使用につながる動物疾病の発生が増加していることがあります。

しかし、重篤な耳毒性、腎毒性、神経筋遮断などの副作用があるため、アミノグリコシド系抗生物質の配合率は低下し、市場成長に悪影響を及ぼすと予想されます。さらに、特定のアミノグリコシド系抗生物質の使用に対する規制当局の不承認も、この産業の成長を低下させる要因になると予想されています。

アミノグリコシド市場レポートハイライト

  • トブラマイシンは予測期間中に市場で大きな成長を示すと予想されます。強力なアミノグリコシド系抗生物質であるトブラマイシンは、グラム陰性菌、特に緑膿菌に対する広域スペクトラムの有効性により、世界のアミノグリコシド系抗生物質産業で重要な役割を果たしています。
  • 投与経路に基づき、市場は注射剤、飼料、乳房内、局所、経口剤、注射剤に分類され、2024年の市場シェアは26.73％で市場をリードしました。
  • 皮膚感染症は予測期間中に最も速いCAGRで成長すると予測されます。皮膚感染症は、その高い有病率とグラム陰性菌感染症の治療におけるアミノグリコシドの有効性により、市場の重要な促進要因となっています。
  • 北米のアミノグリコシド医薬品産業は、2024年の世界売上高シェアの37.60％を占めています。この大きなシェアは、北米で優勢な細菌感染と、何百万人もの人々に影響を与える確立されたヘルスケアインフラに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アミノグリコシド市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/付随市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • アミノグリコシド市場分析ツール
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析
    • パイプライン分析

第4章 アミノグリコシド市場：製品別、推定・動向分析

  • 世界のアミノグリコシド市場：製品ダッシュボード
  • 世界のアミノグリコシド市場：製品変動分析
  • 世界のアミノグリコシド市場（製品別、収益別）
  • ネオマイシン
  • トブラマイシン
  • ゲンタマイシン
  • アミカシン
  • パロモマイシン
  • ストレプトマイシン
  • カナマイシン
  • その他

第5章 アミノグリコシド市場：投与経路別、推定・動向分析

  • 世界のアミノグリコシド市場：投与経路ダッシュボード
  • 世界のアミノグリコシド市場：投与経路変動分析
  • 世界のアミノグリコシド市場（投与経路別、収益別）
  • 注射剤
  • 飼料
  • 乳房内
  • 局所
  • 経口

第6章 アミノグリコシド市場：用途別、推定・動向分析

  • 世界のアミノグリコシド市場：用途ダッシュボード
  • 世界のアミノグリコシド市場：用途変動分析
  • 世界のアミノグリコシド市場（用途別、収益別）
  • 皮膚感染症
  • 尿路感染症と骨盤内疾患
  • 獣医
  • 呼吸器疾患
  • その他

第7章 アミノグリコシド市場：治療、治療クラス、投与経路による地域別、推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018～2030年
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店とチャネルパートナー一覧
    • 主要企業の市場シェア分析、2024年
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
    • Cipla
    • Sun Pharmaceutical Industries Ltd.
    • Lupin
    • Aurobindo Pharma Limited
    • Fresenius Kabi
    • Viatris Inc.
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 3 North America Aminoglycosides Market, by Route of, 2018 - 2030 (USD Million)
  • Table 4 North America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 U.S. Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 8 Canada Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 Canada Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Mexico Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Mexico Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Europe Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Europe Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 17 Germany Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 UK Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 UK Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 France Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 24 France Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Italy Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 Spain Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 30 Spain Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 China Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 36 China Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 38 Japan Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 India Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 44 South Korea Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 South Korea Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Latin America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Brazil Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 MEA Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 MEA Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 South Africa Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Africa Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 UAE Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Aminoglycosides market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and route of administration segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Aminoglycosides market: Drug outlook and key takeaways
  • Fig. 17 Aminoglycosides market: Drug movement analysis
  • Fig. 18 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Non-ergot Aminoglycosides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Aminoglycosides market: Product outlook and key takeaways
  • Fig. 21 Aminoglycosides market: Product movement analysis
  • Fig. 22 Neomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Tobramycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Gentamicin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Amikacin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Paromomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Streptomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Kanamycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Aminoglycosides market: Route of administration outlook and key takeaways
  • Fig. 31 Aminoglycosides market: Route of administration movement analysis
  • Fig. 32 Injectablesmarket estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Feed market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Intra-mammary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Aminoglycosides market: Application outlook and key takeaways
  • Fig. 38 Aminoglycosides market: Application channel movement analysis
  • Fig. 39 Skin Infection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UTI & Pelvic Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Veterinary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Aminoglycosides market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Aminoglycosides market estimates and forecasts, 2018 - 2030 ((USD Million))
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 U.S. Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Canada Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 UK Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 Germany Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 France Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Spain Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Italy Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Denmark Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Sweden Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Target disease prevalence
  • Fig. 81 Norway Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Japan Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 China Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 India Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Target disease prevalence
  • Fig. 95 Australia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Thailand Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 South Korea Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Rest of Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Brazil Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Target disease prevalence
  • Fig. 107 Argentina Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Rest of Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 South Africa Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 Saudi Arabia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 UAE Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 Target disease prevalence
  • Fig. 121 Kuwait Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Rest of MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: 978-1-68038-630-1

Aminoglycoside Market Growth & Trends:

The global aminoglycosides market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.34% from 2025 to 2030. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Aminoglycoside Market Report Highlights:

  • Tobramycin is expected to exhibit significant growth in the market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly Pseudomonas aeruginosa.
  • Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.
  • Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.
  • The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and route of administration outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Aminoglycosides Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of bacterial infections
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Aminoglycosides Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Aminoglycosides Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Aminoglycosides Market: Product Dashboard
  • 4.2. Global Aminoglycosides Market: Product Movement Analysis
  • 4.3. Global Aminoglycosides Market by Product, Revenue
  • 4.4. Neomycin
    • 4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Tobramycin
    • 4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Gentamicin
    • 4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Amikacin
    • 4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Paromomycin
    • 4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Streptomycin
    • 4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Kanamycin
    • 4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Aminoglycosides Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Aminoglycosides Market: Route of Administration Dashboard
  • 5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
  • 5.3. Global Aminoglycosides Market by Route of Administration, Revenue
  • 5.4. Injectable
    • 5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Feed
    • 5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Intra-mammary
    • 5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Topical
    • 5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Oral
    • 5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Aminoglycosides Market: Application Estimates & Trend Analysis

  • 6.1. Global Aminoglycosides Market: Application Dashboard
  • 6.2. Global Aminoglycosides Market: Application Movement Analysis
  • 6.3. Global Aminoglycosides Market by Application, Revenue
  • 6.4. Skin Infection
    • 6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. UTI & Pelvic Diseases
    • 6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Veterinary
    • 6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Respiratory diseases
    • 6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Aminoglycosides Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Merck & Co. Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Teva Pharmaceutical Industries Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Cipla
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sun Pharmaceutical Industries Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Lupin
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Aurobindo Pharma Limited
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Fresenius Kabi
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Viatris Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives